Insider Transactions in Q1 2021 at Neogenomics Inc (NEO)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2021
|
Douglas Matthew Brown Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,655
+4.0%
|
-
|
|
Mar 02
2021
|
Lawrence Martin Weiss Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,276
+4.75%
|
-
|
|
Mar 02
2021
|
George Cardoza President & COO, Lab Ops |
BUY
Grant, award, or other acquisition
|
Direct |
6,207
+1.62%
|
-
|
|
Mar 02
2021
|
Cynthia J Dieter Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,241
+40.2%
|
-
|
|
Mar 02
2021
|
Robert J. Shovlin President, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
6,827
+4.25%
|
-
|
|
Mar 02
2021
|
Robert J. Shovlin President, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
608
-0.41%
|
-
|
|
Mar 02
2021
|
Denise E Pedulla General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
4,345
+6.69%
|
-
|
|
Mar 02
2021
|
Denise E Pedulla General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-0.38%
|
-
|
|
Mar 02
2021
|
Jennifer Balliet VP and Chief Culture Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,862
+6.58%
|
-
|
|
Mar 02
2021
|
Jennifer Balliet VP and Chief Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
173
-0.7%
|
-
|
|
Mar 02
2021
|
William Bonello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,345
+21.92%
|
-
|
|
Mar 02
2021
|
William Bonello Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
432
-3.74%
|
-
|
|
Mar 02
2021
|
Douglas M Van Oort Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,423
+2.23%
|
-
|
|
Mar 02
2021
|
Douglas M Van Oort Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,158
-0.09%
|
-
|
|
Mar 02
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
6,207
+31.44%
|
-
|
|
Mar 02
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
432
-5.57%
|
-
|
|
Mar 01
2021
|
Robert J. Shovlin President, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
742
-0.5%
|
-
|
|
Mar 01
2021
|
Denise E Pedulla General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
212
-0.37%
|
-
|
|
Mar 01
2021
|
Jennifer Balliet VP and Chief Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
212
-0.85%
|
-
|
|
Mar 01
2021
|
William Bonello Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
500
-4.15%
|
-
|
|
Mar 01
2021
|
Douglas M Van Oort Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,339
-0.1%
|
-
|
|
Mar 01
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
169
-2.13%
|
-
|
|
Jan 07
2021
|
Steven C Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,286
+6.22%
|
$224,718
$13.8 P/Share
|
|
Jan 07
2021
|
Steven C Jones Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
100,000
+8.33%
|
$700,000
$7.15 P/Share
|